Literature DB >> 12359266

Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway.

Hiroshi Tomita1, Toru Nakazawa, Eriko Sugano, Toshiaki Abe, Makoto Tamai.   

Abstract

To study whether nipradilol, which is used as an ophthalmic solution for the treatment of glaucoma, has a cytoprotective effect, we investigated its effect on the apoptosis induced by serum withdrawal in PC12 cells. Nipradilol has alpha1- and beta-adrenoceptor-blocking and nitric oxide (NO)-donating properties. We also investigated the effects of timolol, prazosin and S-nitroso-N-acetylpenicillamine (SNAP) on PC12 cell death. Serum withdrawal from PC12 cells resulted in apoptosis, and the survival rate was decreased in a time-dependent manner. The addition of nipradilol to the medium showed a cytoprotective effect on PC12 cell death in a dose-dependent manner, but timolol and prazosin did not. We measured caspase-3 activity to clarify the mechanism of the inhibition of apoptosis in the presence or absence of dithiothreitol (DTT). The caspase-3 activity could be reactivated by DTT. In addition, to investigate the relationship of the cGMP-dependent pathway to the nipradilol-induced cytoprotective effect, we tested the effect of the protein kinase G inhibitor KT5823. KT5823 partially reversed the nipradilol-mediated cytoprotective effect. These results indicate that the cytoprotective effect of nipradilol in PC12 cell death was due to the caspase-3 inhibition mediated by NO-related S-nitrosylation and activation of protein kinase G.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359266     DOI: 10.1016/s0014-2999(02)02329-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

Review 1.  S-Nitrosylation Regulates Cell Survival and Death in the Central Nervous System.

Authors:  Yoshiki Koriyama; Ayako Furukawa
Journal:  Neurochem Res       Date:  2017-05-18       Impact factor: 3.996

2.  Visual field loss in patients with normal-tension glaucoma under topical nipradilol or timolol: subgroup and subfield analyses of the nipradilol-timolol study.

Authors:  Makoto Araie; Shiroaki Shirato; Yoshio Yamazaki; Yoshiaki Kitazawa; Yasuo Ohashi
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

3.  Clinical efficacy of topical nipradilol and timolol on visual field performance in normal-tension glaucoma: a multicenter, randomized, double-masked comparative study.

Authors:  Makoto Araie; Shiroaki Shirato; Yoshio Yamazaki; Yoshiaki Kitazawa; Yasuo Ohashi
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

4.  Recent advances in pharmacotherapy of glaucoma.

Authors:  S K Gupta; Galpalli Niranjan D; S S Agrawal; Sushma Srivastava; Rohit Saxena
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

5.  Establishment of monocular-limited photoreceptor degeneration models in rabbits.

Authors:  Hitomi Isago; Eriko Sugano; Namie Murayama; Makoto Tamai; Hiroshi Tomita
Journal:  BMC Ophthalmol       Date:  2013-05-17       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.